Navigation Links
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma

are a compelling factor to drive forth the clinical development of AP 12009 in high-grade glioma and in other solid tumors.” The American Society of Clinical Oncology provides an audio version of the poster discussion by Prof. Wong. The virtual meeting presentation can be found following this link: http://www.antisense-pharma.com/publications/f_publications.htm General Background on AP 12009 and TGF-beta 2 AP 12009 is an antisense drug - a phosphorothioate oligodeoxynucleotide - designed to selectively downregulate the production of transforming growth factor-beta 2 (TGF-beta 2) at the translational level. TGF-beta 2 plays a pivotal role as a multimodally acting cytokine by regulating key mechanisms of tumor progression. Immunosuppression, invasion and migration, proliferation and angiogenesis are simultaneously promoted in a variety of malignant tumors.This multiple impact on cancer cells is inhibited by AP 12009 (3, 4).

General Background on High-Grade Glioma Anaplastic astrocytoma and glioblastoma are the two most common forms of primary brain tumor, a diagnosis with high unmet medical need. Adults as well as children can be affected, although the age peak is at 45-65 years. Current therapies comprise surgery, radiation and/or chemotherapy. Despite recent advances the prognosis for these patients is still poor, with 94% dying within two years of initial diagnosis.

About Antisense Pharma GmbH Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The agents specifically block the synthesis of key cancer proteins. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award.

Literature (1) Bogdahn U., et. a
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:12/17/2009)... Decision Resources, one of the world,s leading research ... finds that the cost of Roche/Chugai,s Avastin, followed ... are cited most frequently by surveyed oncologists as ... non-small-cell lung cancer treatment in Germany, France, Italy, ... Special European Physician & Payer Forum report entitled ...
(Date:12/17/2009)... ORLANDO, Fla., Dec. 17 MedX Limited, ... -branded medical exercise equipment and a subsidiary of ... the sale of 227 MedX exercise ... list of countries, including Australia, Germany, India, Scotland, ... sold MedX equipment will be used ...
(Date:12/17/2009)... Inc., (OTC Bulletin Board: SCIE) disclosed today that its ... letter to shareholders: ,, As the end of the ... the recent closing of a $4.3 million round of ... ramping our business performance as we head into 2010. ... force. We are increasing our sales and marketing activities ...
Breaking Medicine Technology:Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 2WellTek Subsidiary MedX Limited Increases Presence in Global Market 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 4SpectraScience Releases Shareholder Newsletter 2SpectraScience Releases Shareholder Newsletter 3SpectraScience Releases Shareholder Newsletter 4SpectraScience Releases Shareholder Newsletter 5Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 1Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 2Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 3Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 4Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 5Abbott Cuts Use of Oil and Coal by 35 Percent 5108 1Abbott Cuts Use of Oil and Coal by 35 Percent 5108 2Abbott Cuts Use of Oil and Coal by 35 Percent 5108 3Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 1Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 2
... — SciClone,Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that ... Meeting of,the American Society of Clinical Oncology in ... (thymalfasin, thymosin alpha 1) Poster,Presentation ,A large first-line, ... (T?1) plus Dacarbazine (DTIC) with or without,Interferon alpha ...
... WIRE)--Apr 30, 2007 - Insmed Inc.,(Nasdaq:INSM) today ... clinical study of the company's drug,IPLEX(TM) in ... (HARS)., Preliminary results from the study, being ... showed that three months,of 0.5 mg/kg/day IPLEX ...
Other Medicine Technology:SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO 2Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 2Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 3Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 4
(Date:12/17/2009)... nurses now able to access trusted medical information using virtually ... ... MA (PRWEB) December 17, 2009 -- Skyscape, Inc., the world’s ... and the Internet, has launched a mobile clinical decision application ... are now available on most smart phone devices, making the ...
(Date:12/17/2009)... -- Reportlinker.com announces that a new market ... ,, India Healthcare IT Investment Opportunities, ... http://www.reportlinker.com/p0169911/India-Healthcare-IT-Investment-Opportunities-Analysis-and-Forecasts-to-2015.html ,, India Healthcare IT ... ,, Summary ,, This report ... and data relating to India healthcare IT ...
(Date:12/17/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, http://www.reportlinker.com/p0169972/Top-Ten-Worlds-Leading-Life-Science-Intermediates-Companies.html ... competitive environment is widely recognized as ... responsibilities, the task crucial to business ... factual competitive intelligence is vital to ...
(Date:12/17/2009)... Today, CDC,s Morbidity and Mortality Weekly Report (MMWR) ... state-level epidemiologists has decreased steadily since 2004, with ... There was also a substantial decrease in core ... capacity for bioterrorism and emergency response. ... health, substance abuse, and oral health, basic epidemiology ...
(Date:12/17/2009)... KONG, Dec. 17 /PRNewswire-Asia/ -- China,s leading high-tech,healthcare ... "the,Group"; Stock Code: 801) is pleased to announce ... Limited (FunTalk), formerly known as,Pypo China Holdings Limited, ... FTLK ) after a successful secondary offering. The ... morning (Eastern Time). , ...
Breaking Medicine News(10 mins):Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 4Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 2Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 3Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 4Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 5Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 6Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 7Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 8Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2Health News:Golden Meditech's Associate Company Debuted on NASDAQ 2
... this 'Brave New World' fact is truly becoming stranger than ... creation of artificial // human sperms from a ... from human bone marrow are now the new ... be worked upon to benefit infertile men. ,The pioneering ...
... Canadian soldiers posted to battle in Afghanistan are increasingly ... say// concerned experts. ,Ontario’s ombudsman Andre ... It was seen that a center for treatment of ... poor funding due to government bodies unwilling to take ...
... from Université Laval’s Faculty of Medicine have discovered that ... a pathological reaction in skin// cells. ... dubbed "instant anti-aging face-lifts." This compound, as well as ... creams, lipsticks, shampoos, soaps, and baby lotions, although the ...
... U.S., is about to embark on an ambitious plan promising up ... ,The state is expected to set limits ... to gain health insurance. This move is hoped to mean that ... to afford premiums and vital medical care. ,The proposal ...
... undertaken what is described as the biggest DNA analysis of ... biggest single leap in the understanding of how genes dictate ... new wave of tailored therapies and tests to predict the ... ,A coalition of 50 groups, including 24 leading human geneticists, ...
... phase of the National AIDS Control Program (NACP), set ... strategies vary widely from state to state. States// are ... declared numbers of the HIV/AIDS infected. But there is ... to state. ,The budgetary allocation also differs, ...
Other Medicine News:Health News:Breakthrough Discovery- Human Sperms From Bone Marrow 2Health News:Collateral Damage-Children Of Canadian Soldiers Suffer 2Health News:Anti-wrinkle Compound Causes Pathological Reaction in Skin Cells 2Health News:Health Insurance For Almost Everyone In Massachusetts 2Health News:UK Scientists to Reveal Genetic Secrets Behind Serious Illnesses 2Health News:When 'prevalence' Makes for Disparity in AIDS Care 2Health News:When 'prevalence' Makes for Disparity in AIDS Care 3
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
Medicine Products: